Skip to content
General News, Medical Health Aged Care

Monash accelerates medical innovation and development of life-saving treatments

Monash University 2 mins read

Victorian Deputy Premier and Minister for Medical Research the Hon Ben Carroll today officially opened the newly built Medicines Manufacturing Innovation Centre (MMIC) within the heart of the Monash Technology Precinct, Clayton. 

 

Funded through an $8.58 million investment from the Victorian Higher Education State Investment Fund and $4 million from Monash University, MMIC’s expansion to Clayton builds on the Centre’s work based at the Monash Institute of Pharmaceutical Sciences (MIPS) in Parkville to provide further opportunities for innovation across medicine formulation, resolving manufacturing process challenges and building supply of highly-skilled, industry ready candidates for the workforce. 

 

Minister Carroll also announced a grant awarded to MMIC by the Cumming Global Centre for Pandemic Therapeutics (Cumming Global Centre). The grant will fund the development of a potential new therapeutic agent for the treatment of respiratory infections and inflammation, with the aim to help safeguard the community against both existing and future viruses.

 

Director of MMIC, Professor Michelle McIntosh said the Centre’s expansion to Clayton will deliver far-reaching benefits to the Victorian community.

 

“This new facility represents a significant advancement in Victoria’s research commercialisation opportunities. Our team of dedicated pharmaceutical scientists are committed to driving forward the end-to-end development of a range of medicines using state-of-the-art technology, from laboratory-scale projects right through to local manufacture of medicines for clinical trials,” Professor McIntosh said.

 

“We’re also thrilled to have Cumming Global Centre’s Professor Sharon Lewin join us for the MMIC launch. Fostering collaboration between research institutes is central to MMICs mission, and we are excited to be working with Professor Lewin and her team to progress a new treatment for respiratory viruses and further strengthen Australia’s resilience to future health emergencies,” Professor McIntosh said. 

 

Inaugural Director of the Cumming Global Centre, Melbourne Laureate Professor Sharon Lewin congratulated Professor McIntosh on the grant and said she looks forward to seeing the project come to fruition.

 

“In a globally competitive process, Professor McIntosh’s exploration of an innovative delivery system to treat future respiratory viruses stood out for both scientific excellence and its alignment to the Centre’s mission to advance the science behind therapeutics for pathogens of pandemic potential,” Professor Lewin said. 

Monash University Vice-Chancellor and President Professor Sharon Pickering said the permanent MMIC facility is an important new addition to the Monash Technology Precinct – a world class hub of research, industry, innovation and talent that is part of Victoria’s largest employment precinct outside the Melbourne CBD.

“This new facility will further strengthen the research and development capability of the Monash Technology Precinct innovation ecosystem, joining world-leading research and technology organisations such the CSIRO, the Melbourne Centre for Nanofabrication, the Victorian Heart Hospital and the soon-to-be completed Moderna manufacturing facility.

 

“By being located in the world-class Monash Technology Precinct, the MMIC will provide our researchers, precinct partners and local and international companies the opportunity to develop, test and scale-up new medicines here in Australia without going off-shore.”

MMIC Clayton is a purpose designed and built facility including laboratory and office space, co-located with the Australian Synchrotron in the heart of the Monash Technology Precinct, promoting further economic opportunities and growing employment.

Monash University ranked number two globally in the 2024 QS World University Rankings by Subject for Pharmacy and Pharmacology.

ENDS


Contact details:

Kate Carthew

0438 674 814

kate.carthew@monash.edu 

More from this category

  • Medical Health Aged Care
  • 21/10/2024
  • 16:55
Royal Australian College of GPs

RACGP welcomes Tasmanian health minister Jacquie Petrusma

The Royal Australian College of GPs (RACGP) has welcomed new Minister for Health in Tasmania Jacquie Petrusma MP and praised outgoing Minister for Health Guy Barnett. Mr Barnett will take on the role of Treasurer alongside his Attorney-General and Minister for Justice portfolios. Ms Petrusma, who was a registered nurse before being elected to state parliament, will also be Minister for Aboriginal Affairs and Minister for Veterans’ ­Affairs. Mr Barnett joined RACGP Tasmania to welcome 40 new specialist GPs at a fellowship ceremony in Hobart last month. RACGP Tasmania Chair Dr Toby Gardner thanked Mr Barnett for his work in…

  • Contains:
  • Medical Health Aged Care
  • 21/10/2024
  • 16:10
Galderma

ASDS 2024: New Phase III READY-4 Data Demonstrate Long-Term Safety and Efficacy of Galderma’s RelabotulinumtoxinA (Relfydess(TM))

First results from the phase III READY-4 trial demonstrate the long-term safety of repeated injections of RelabotulinumtoxinA for both frown lines and crow’s feet,…

  • Contains:
  • Medical Health Aged Care
  • 21/10/2024
  • 15:11
Angelini Pharma

Angelini Pharma Enters Into An Exclusive Option Agreement With Cureverse to License Global Development and Commercialization Rights For A Novel and Innovative Clinical-Stage Brain Health Asset

The agreement gives Angelini Pharma an option to exclusive licensing rights to develop and commercialize CV-011, a clinical Phase 1 investigational novel compound with broad potential to treat brain health diseasesCureverse receives undisclosed upfront payments and is eligible for future milestone-dependent payments and royalties, while retaining rights to commercialize CV-01 in the Republic of Korea, China, Hong Kong, Macau and TaiwanThe collaboration builds on Angelini Pharma’s strong portfolio and deep therapeutic expertise in brain health as well as Cureverse’s early development know-how and capabilitiesROME, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Angelini Pharma, part of the privately owned Angelini Industries, and…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.